Association of mammalian target of rapamycin gene locus rs1883965 polymorphism with kawasaki disease

doi:10.3877/cma.j.issn.2095-655X.2018.03.006

Abstract

Abstract:

Objective

To investigate the genetic association of mammalian target of rapamycin (mTOR) gene locus rs1883965 polymorphism with kawasaki disease (KD).

Methods

This is a case-control study, 100 patients with KD were enrolled from inpatients and follow-up outpatients who visited the Third Xiangya Hospital of Central South University during January 2012 to December 2015, and 100 healthy subjects were enrolled from the health management center of the Third Xiangya Hospital of Central South University in this study. The genotype of locus rs1883965 of mTOR was detected by polymerase chain reaction and gene sequencing.

Results

For locus rs1883965 polymorphism in mTOR gene, there were no significant differences between KD patients and the controls in genotype frequencies of CC, CT and TT (81.0%, 19.0%, 0%; 85.0%, 14.0%, 1.0%), and allele frequencies of C and T (90.5%, 9.5%; 92.0%, 8.0%) (χ²=1.85, 0.28, all P>0.05). For locus rs1883965 polymorphism in mTOR gene, KD patients with coronary artery lesion (CAL) in genotype frequencies of CC, CT and TT (80.0%, 20.0%, 0.0%) and allele frequencies of C and T(90.0%, 10.0%), and KD patients without CAL in genotype frequencies of CC, CT and TT (81.2%, 18.8%, 0%) and allele frequencies of C and T(90.6%, 9.4%). There were no significant differences between the two groups (χ²=0.02, 0.02, all P>0.05).

Conclusion

No association is found between rs1883965 polymorphism in mTOR gene and the risk of KD and its complication of CAL in this study.

Key words: Mammalian target of rapamycin, Mucocutaneous lymph node syndrome, Polymorphism, single nucleotide, Coronary vessels

Fang Chen, Jie Luo, Shentang Li, Yeping Luo, Zuocheng Yang. Association of mammalian target of rapamycin gene locus rs1883965 polymorphism with kawasaki disease[J]. Chinese Journal of Diagnostics(Electronic Edition), 2018, 06(03): 172-176.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2018.03.006

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2018/V06/I03/172

Figures/Tables 4

References 21

[1]	Cargnello M，Tcherkezian J，Roux PP.The expanding role of mTOR in cancer cell growth and proliferation[J]．Mutagenesis，2015，30(2):169-176.
[2]	Jia G，Aroor AR，Martinez-Lemus LA，et al.Overnutrition，mTOR signaling，and cardiovascular diseases[J]．Am J Physiol Regul Integr Comp Physiol，2014，307(10):1198-1206.
[3]	Yang Z，Ming XF.mTOR signalling：the molecular interface connecting metabolic stress，aging and cardiovascular diseases[J]．Obes Rev，2012，13(Suppl 2):58-68.
[4]	Suhara T，Baba Y，Shimada BK，et al.The mTOR signaling pathway in myocardial dysfunction in type 2 diabetes mellitus[J]．Curr Diab Rep，2017，17(6):38.
[5]	诸福棠．实用儿科学[M]．北京：人民卫生出版社，2002：698-704.
[6]	Cho MA，Choi YJ，Jung JW.Affects of " age at diagnosis" on coronary artery lesions in patients with incomplete kawasaki disease[J]．Korean Circ J，2010，40(6):283-287.
[7]	Dietz SM，Van Stijn D，Burgner D，et al.Dissecting Kawasaki disease：a state-of-the-art review[J]．Eur J Pediatr，2017，176(8):995-1009.
[8]	Ueno K, Ninomiya Y, Hazeki D. Disruption of endothelial cell homeostasis plays a key role in the early pathogenesis of coronary artery abnormalities in kawasaki disease[J]．Sci Rep，2017(7):43719.
[9]	陈芳，江杰，李卓颖，等．谷胱甘肽过氧化物酶1基因多态性与川崎病的关联性分析[J]．中国动脉硬化杂志，2015，23(3):290-294.
[10]	Li Z，Han D，Jiang J，et al.Association of PECAM-1 gene polymorphisms with kawasaki disease in Chinese children[J]．Dis Markers，2017(2017):2960502.
[11]	Chang LS，Hsu YW，Lu CC，et al.CYP2E1 gene polymorphisms related to the formation of coronary artery lesions in kawasaki disease[J]．Pediatr Infect Dis J，2017，36(11):1039-1043.
[12]	Zining J，Lu X，Caiyun H，et al.Genetic polymorphisms of mTOR and cancer risk：a systematic review and updated meta-analysis[J]．Oncotarget，2016，7(35):57464-57480.
[13]	Huang K，Fingar DC.Growing knowledge of the mTOR signaling network[J]．Semin Cell Dev Biol，2014(36):79-90.
[14]	Angliker N，Burri M，Zaichuk M，et al.mTORC1 and mTORC2 have largely distinct functions in purkinje cells[J]．Eur J Neurosci，2015，42(8):2595-2612.
[15]	Chen R，Davydov EV，Sirota M，et al.Non-synonymous and synonymous coding SNPs show similar likelihood and effect size of human disease association[J]．PLoS One，2010，5(10):e13574.
[16]	Das A，Reis F，Maejima Y，et al.mTOR signaling in cardiometabolic disease，cancer and aging[J]．Oxid Med Cell Longev，2017(2017):6018675.
[17]	Korybalska K，Kawka E，Breborowicz A，et al.The role of mTOR inhibitors and HMG-CoA reductase inhibitors on young and old endothelial cellfunctions，critical for re-endothelialisation after percutaneous coronary intervention：an in vitrostudy[J]．J Physiol Pharmacol，2017，68(3):397-405.
[18]	Korybalska K，Kawka E，Breborowicz A，et al.The role of mTOR inhibitors and HMG-CoA reductase inhibitors on young and old endothelial cell functions，critical for re-endothelialisation after percutaneous coronary intervention：an in vitro study[J]．J Physiol Pharmacol，2017，68(3):397-405.
[19]	Jahrling JB，Lin AL，DeRosa N，et al.mTOR drives cerebral blood flow and memory deficits in LDLR-/-mice modeling atherosclerosis and vascular cognitive impairment[J]．J Cereb Blood Flow Metab，2018，38(1):58-74.
[20]	Martinet W，De Loof H，De Meyer GR.mTOR inhibition：a promising strategy for stabilization of atherosclerotic plaques[J]．Atherosclerosis，2014，233(2):601-607.
[21]	Kurdi A，De Meyer GR，Martinet W．Potential therapeutic effects of mTOR inhibition in atherosclerosis[J]．Br J Clin Pharmacol，2016，82(5):1267-1279.

组别	例数	基因型			等位基因
组别	例数	CC	CT	TT	C	T
健康对照组	100	85(85.0)	14(14.0)	1(1.0)	184(92.0)	16(8.0)
川崎病组	100	81(81.0)	19(19.0)	0(0.0)	181(90.5)	19(9.5)
χ²值	?	1.85			0.28
P值	?	0.39			0.59

组别	例数	基因型			等位基因
组别	例数	CC	CT	TT	C	T
健康对照组	100	85(85.0)	14(14.0)	1(1.0)	184(92.0)	16(8.0)
川崎病组	100	81(81.0)	19(19.0)	0(0.0)	181(90.5)	19(9.5)
χ²值	?	1.85			0.28
P值	?	0.39			0.59

组别	例数	基因型			等位基因
组别	例数	CC	CT	TT	C	T
KD-WO组	80	65(81.2)	15(18.8)	0(0.0)	145(90.6)	15(9.4)
KD-CAL组	20	16(80.0)	4(20.0)	0(0.0)	36(90.0)	4(10.0)
χ²值	?	0.02			0.02
P值	?	0.89			0.90

组别	例数	基因型			等位基因
组别	例数	CC	CT	TT	C	T
KD-WO组	80	65(81.2)	15(18.8)	0(0.0)	145(90.6)	15(9.4)
KD-CAL组	20	16(80.0)	4(20.0)	0(0.0)	36(90.0)	4(10.0)
χ²值	?	0.02			0.02
P值	?	0.89			0.90

Please choose a citation manager

Content to export